Physician profile
Hao Feng
NPI 1033520556
$12,138.54
in general payments reported to CMS, 2019-2025
14 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what 89% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $43.45 · 2021: $277 · 2022: $2,172 · 2024: $7,078 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,100 · Food and Beverage: $77.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,100.00 |
| Food and Beverage | $77.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,354.89 | 2019-2025 | |
| Ocular Therapeutix, INC. | $184.97 | 2021-2024 | Dextenza |
| Allergan, INC. | $152.34 | 2019 | |
| Janssen Biotech, INC. | $148.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $64.41 | 2022 | |
| Janssen Scientific Affairs, LLC | $34.85 | 2022 | |
| Sun Pharmaceutical Industries INC. | $29.52 | 2020-2021 | |
| Genzyme Corporation | $28.89 | 2024 | |
| Pfizer INC. | $28.84 | 2024 | |
| Galderma Laboratories, L.P. | $28.57 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.05 | 2021 | |
| Lilly USA, LLC | $19.20 | 2021 | |
| Leo Pharma INC. | $18.02 | 2021 | |
| Organogenesis INC. | $17.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hao Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.